Geode Capital Management LLC Has $44.48 Million Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Geode Capital Management LLC lifted its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 5.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,105,487 shares of the company's stock after acquiring an additional 52,263 shares during the period. Geode Capital Management LLC owned 1.71% of Kymera Therapeutics worth $44,484,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Blue Trust Inc. grew its position in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares during the last quarter. KBC Group NV boosted its position in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company's stock worth $87,000 after buying an additional 752 shares during the period. KLP Kapitalforvaltning AS bought a new position in Kymera Therapeutics in the 4th quarter worth approximately $310,000. Arizona State Retirement System increased its position in Kymera Therapeutics by 15.5% in the 4th quarter. Arizona State Retirement System now owns 11,221 shares of the company's stock valued at $451,000 after acquiring an additional 1,503 shares during the period. Finally, Teacher Retirement System of Texas increased its position in Kymera Therapeutics by 35.8% in the 4th quarter. Teacher Retirement System of Texas now owns 11,490 shares of the company's stock valued at $462,000 after acquiring an additional 3,026 shares during the period.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock traded up $0.95 during trading hours on Friday, hitting $25.97. The company had a trading volume of 468,785 shares, compared to its average volume of 549,679. The firm's fifty day moving average is $30.47 and its 200-day moving average is $39.00. The firm has a market capitalization of $1.69 billion, a P/E ratio of -11.10 and a beta of 2.22. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $7.39 million for the quarter, compared to analyst estimates of $14.81 million. Analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Ellen Chiniara sold 2,241 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. This represents a 2.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 10,659 shares of company stock worth $324,567. Insiders own 15.82% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Citigroup assumed coverage on shares of Kymera Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective for the company. HC Wainwright raised their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Leerink Partners reiterated an "outperform" rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, Stephens restated an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $56.36.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.